Full text is available at the source.
Abstract
Medicare costs for phosphate binders for US dialysis patients exceeded $1.5 billion in 2015.
- Costs for mineral and bone disorder medications in dialysis patients have increased faster than overall Part D medication costs.
- Extensive use of phosphate binders has occurred despite insufficient evidence showing their effectiveness in improving clinical outcomes.
- Updated trends in phosphate-binder use, calcium and phosphorus values, and costs were analyzed using data from the US Renal Data System and CMS.
- A need for US Food and Drug Administration guidance on the clinical evaluation of new phosphate binders is indicated.
- Funding for a clinical trial to explore the impact of phosphate concentrations on clinical outcomes is suggested.
Simplified